Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
-
Peter Staib
Abstract
It has been reported that the dimeric isoform of the enzyme pyruvate kinase M2 was overexpressed in various solid tumor cells. Hence, it was suggested that circulating levels of the so-called tumor M2-pyruvate kinase (Tu M2-PK) could be used as a tumor marker for monitoring systemic therapies of various solid tumors. We analyzed its validity as a tumor marker by comparing plasma levels of Tu M2-PK in patients with different non-malignant diseases to levels in healthy individuals and in patients with hematological diseases. Plasma levels of Tu M2-PK were measured using an ELISA assay in a total of 284 patients. The mean Tu M2-PK concentration of 32 U/mL was significantly higher in the group of patients with hematological malignancies (n=121) (p<0.001). However, 37% of healthy individuals (n=63) and 44% of patients with non-malignant diseases (n=100), especially patients with an acute inflammatory reaction (67%), were found to have elevated levels of Tu M2-PK using a cutoff level of 15U/mL. The specificity was 59% and the sensitivity was 51%. There was no significant correlation between the prevalence of a hematological malignancy and positive Tu M2-PK result. Thus, our data imply that Tu M2-PK is not a useful tumor marker for hematological malignancies and solid tumors, as a significant number of false positive results were detected in healthy individuals and patients with non-malignant diseases.
References
1. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 2002; 87(Suppl 1):S23–9.10.1079/BJN2001454Search in Google Scholar
2. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F, et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999; 19:849–51.Search in Google Scholar
3. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20:4965–8.Search in Google Scholar
4. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol 2001; 22:282–5.10.1159/000050628Search in Google Scholar
5. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49:1149–55.10.1023/B:DDAS.0000037803.32013.aaSearch in Google Scholar
6. Kaura B, Bagga R, Patel FD. Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 2004; 30:193–6.10.1111/j.1447-0756.2004.00187.xSearch in Google Scholar
7. Hudelist G, Kostler W, Czerwenka K, Kubista E, Singer CF. Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook. Methods Find Exp Clin Pharmacol 2004; 26:201–10.10.1358/mf.2004.26.3.809727Search in Google Scholar
8. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91:980–4.10.1038/sj.bjc.6602033Search in Google Scholar
9. Schneider J, Neu K, Velcovsky HG, Morr H, Eigenbrodt E. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 2003; 193:91–8.10.1016/S0304-3835(02)00720-6Search in Google Scholar
10. Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, et al. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 31:358–62.10.1007/s00240-003-0331-4Search in Google Scholar PubMed
11. Oremek GM, Rox S, Mitrou P, Sapoutzis N, Sauer-Eppel H. Tumor M2-PK levels in haematological malignancies. Anticancer Res 2003; 23:1135–8.Search in Google Scholar
12. Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res 2000; 20:5095–8.Search in Google Scholar
13. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68:1075–82.Search in Google Scholar
14. Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res 2003; 23:1127–30.Search in Google Scholar
15. Oremek GM, Muller R, Sapoutzis N, Wigand R. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases. Anticancer Res 2003; 23:1131–4.Search in Google Scholar
16. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients]. Urologe A 2000; 39:554–6.10.1007/s001200050410Search in Google Scholar PubMed
17. Varga Z, Hegele A, Stief T, Heidenreich A, Hofmann R. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker? Urol Res 2002; 30:122–5.10.1007/s00240-002-0246-5Search in Google Scholar PubMed
18. Hegele A, Varga Z, Kosche B, Stief T, Heidenreich A, Hofmann R. Pyruvate kinase type tumor M2 in urological malignancies. Urol Int 2003; 70:55–8.10.1159/000067707Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
Articles in the same Issue
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
